Hungary's Gedeon Richter announced licensing and supply agreements with Eli Lilly on 12 November 2026, creating a potential American commercial route for its estetrol-based menopause treatment. Lilly's option to market the existing medicine jointly in the United States depends on regulatory approval; the agreements themselves also require competition clearance and other closing conditions.1
The licence separately grants worldwide rights to develop medicines combining Richter's estetrol with Lilly compounds. Richter would supply the active ingredient and, if Lilly exercises its option, the existing monotherapy. These are distinct commercial arrangements, rather than evidence that American sales have begun.1
Richter's Hungarian announcement describes the medicine as:
jelenleg az FDA értékelése alatt áll
currently under FDA review.1
US review
On 14 October, Richter said the US Food and Drug Administration had accepted its new-drug application for Fylrevy. It expected the review to finish in the third quarter of 2027. That date is the company's stated expectation, and acceptance for review is a different milestone from permission to sell the medicine.3
The American application concerns moderate to severe vasomotor symptoms associated with menopause, including hot flushes. Richter described the treatment as an oral oestrogen therapy.3
European sales
The European Medicines Agency records an EU-wide marketing authorisation issued on 26 March 2026, with Richter in Budapest as the authorisation holder. The product treats oestrogen-deficiency symptoms in postmenopausal women. Its authorisation follows the European assessment of the medicine's benefits and risks; it does not determine the outcome of the separate American application.2
The EMA also identifies the product as subject to additional monitoring. Recommendations and precautions sit in its authorised product information, and suspected side effects continue to be evaluated. For cross-border business, authorisation therefore begins an ongoing regulated supply relationship, rather than ending the manufacturer's regulatory responsibilities once a market opens.2
Richter's October statement named Hungary, the Czech Republic, Slovakia, Finland and Sweden as markets where Fylrevy was already commercialised. It did not present those launches as a US sales record.3
Existing earnings
The company's results published on 10 November reported pharmaceutical revenue of HUF686.5 billion for the first nine months, up 2.6% in reported currency. At constant exchange rates, growth was 11.7%. Richter attributed the difference largely to currency movements, particularly the stronger forint. Those totals cover its pharmaceutical business, not receipts from the newly announced Lilly arrangement.4
Women's healthcare revenue grew 11% at constant exchange rates over that period. Richter named Ryeqo, Lenzetto and Drovelis as its principal growth drivers in the division and described Fylrevy's launch as a focus project. The results establish an existing business base, with several products contributing before the new supply agreement.4
The next American milestone remains the FDA review's completion, expected by Richter in the third quarter of 2027.3